logo

FDA Calendar

Company Name GlaxoSmithKline PLC
GSK.L, GSK
Drug Name Cabenuva (resubmitted NDA)
Event Name FDA decision on Cabenuva to treat HIV-1 infection in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine.
Event Date Mid 2021
Outcome Date 01/21/2021
Outcome FDA approved Cabenuva on Jan.21, 2021
Drug Status
Rival Drugs Cabenuva would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
Market Potential
Other Approvals
News
Return to FDA Calendar

Editors Pick
Fast-food giant McDonald's said it will be raising hourly wages for more than 36,500 hardworking employees at McDonald's-owned restaurants by an average of 10 percent to make it among the industry-leading pay and benefits package. These increases, which have already begun, will be rolled out over the next several months. Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints,... General Mills Inc. (GIS) agreed to buy Tyson Foods' (TSN) pet treats business for $1.2 billion in cash, the companies said in a statement on Friday. The transaction includes the Nudges, Top Chews and True Chews brands. General Mills will also acquire a manufacturing facility in Independence, Iowa.
The Centers for Disease Control and Prevention updated its mask guidance for fully vaccinated Americans, allowing them to go mask-free in outdoor and most indoor settings. The guidance, updated on Thursday, however, calls for wearing masks in crowded indoor settings like buses, planes, hospitals, prisons and homeless shelters. Announcing it at a news conference, President Joe Biden said, "If yo
The Centers for Disease Control and Prevention has granted final approval to administer BioNTech-Pfizer COVID vaccine for adolescents in the age group of 12 to 15 years. President Joe Biden described this as another giant step in the United States' fight against the pandemic. "I sincerely think the scientists, researchers, and clinical trial participants; they've all made this possible. Because
Amgen (AMGN) and AstraZeneca Thursday said results from the Phase 3 study of tezepelumab in severe asthma patients, dubbed Navigator, have been published in the New England Journal of Medicine.
Read More